Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
MoonLake submits BLA for sonelokimab in hidradenitis suppurativaSep 30Regulatory milestoneMoonLake Immunotherapeutics AGsonelokimab
MoonLake posts Phase 2 results for sonelokimab in psoriatic arthritis and hidradenitis suppurativaSep 10Weekly roundup, 2 itemsMoonLake Immunotherapeutics AGsonelokimab
MoonLake reports positive Phase 3 IZAR-1 results in psoriatic arthritis, Q2 2026 earningsAug 10Clinical readoutMoonLake Immunotherapeutics AGsonelokimab